Interferon and Copolymer I Treatment in Multiple Sclerosis: Clinical and Pathobiological Implications

  • Kenneth P. Johnson
  • Hillel S. Panitch
Part of the NATO ASI Series book series (NSSA, volume 258)

Abstract

Multiple sclerosis (MS), although well-described clinically and pathologically for over 120 years, is only now poised for a new era of improved therapy brought about primarily by findings obtained from clinical research. Over the past 12 years, various investigations of new treatments have not only identified effective agents but have provided unexpected new insights into the basic mechanisms of disease activity in MS. The combination of carefully designed and conducted clinical trials, coupled with serial MRI studies of the brain, has allowed us to determine the therapeutic benefit of one and perhaps two treatments with low risk and toxicity which are likely to be available to the general MS community within 6 to 24 months.

Keywords

Placebo Fatigue Toxicity Europe Tyrosine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    B.G. Weinshenker, B. Bass, G.P.A. Rice, J. Noseworthy, W. Carriere, et al, The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course, Brain 112: 1419–1428 (1989).PubMedCrossRefGoogle Scholar
  2. 2.
    The IFN-Multiple Sclerosis Study Group, Interferon-beta 1 B is effective in relapsing-remitting multiple sclerosis: Clinical results of a multicenter, randomized, double blind, placebo controlled trial, Neurol. 43: in press (1993).Google Scholar
  3. 3.
    A. Isaacs, J. Lindenmann, Virus interference, I. The interferon, Proceedings of the Royal Society of London (Biology) 147: 258–267 (1957).CrossRefGoogle Scholar
  4. 4.
    H.S. Panitch, Interferons in multiple sclerosis. A review of the evidence, Drugs. 44(6): 946–962 (1992).Google Scholar
  5. 5.
    P.A. Neighbor, A.E. Miller, B.R. Bloom, Interferon responses of leucocytes in multiple sclerosis, Neurol. 31: 561–566 (1981).CrossRefGoogle Scholar
  6. 6.
    S. Dhib-Jalbut, D.E. McFarlin, Immunology of multiple sclerosis, Ann Allergy. 64: 433–444 (1989).Google Scholar
  7. 7.
    H.S. Panitch, J.S. Folus, K.P. Johnson, Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis, Abstract, Ann Neurol. 22: 139 (1987a).Google Scholar
  8. 8.
    A. Noronha, A. Toscas, M.A. Jensen, Interferon beta augments suppressor cell function in multiple sclerosis, Ann Neurol. 27: 207–210 (1990).PubMedCrossRefGoogle Scholar
  9. 9.
    H.S. Panitch, J.S. Folus, K.P. Johnson, Activated suppressor cells inhibit synthesis of interferon-―in patients with multiple sclerosis patients and normal subjects, Abstract, J Neuroimmunol. In press (1992b).Google Scholar
  10. 10.
    R. Arnon, Experimental allergic encephalomyelitis-susceptibility and suppression, Immunol. Rev. 55: 5–30 (1981).PubMedCrossRefGoogle Scholar
  11. 11.
    M.B. Bornstein, A. Miller, S. Slagle et al, A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosisA pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis, N Engl J Med. 317: 408–414 (1987).Google Scholar
  12. 12.
    M.B. Bornstein, K.P. Johnson, Treatment of multiple sclerosis with Copolymer I, in: “Handbook of Multiple Sclerosis,” S.D. Cook, ed., Marcel Dekker, Inc., New York and Basel (1990).Google Scholar
  13. 13.
    M.B. Bornstein, A. Miller, S. Slagle et al, A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis, Neurol. 41: 533–539 (1991).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Kenneth P. Johnson
    • 1
  • Hillel S. Panitch
    • 1
  1. 1.Department of NeurologyUniversity of Maryland at BaltimoreBaltimoreUSA

Personalised recommendations